

Table 2 First and second line treatment distribution among the study sample: patients aged ≥ 18 years with T2DM ($n = 348$), Lebanon, 2015–2019

Treatment	No.	%
First-line therapy		
Met (Mono)	198	56.9
SU (Mono)	22	6.3
DPP-4i (Mono)	5	1.4
Other (Mono)	3	0.9
Met+SU (Dual)	49	14.1
Met+DPP-4i (Dual)	32	9.2
Met+other (Dual)	2	0.6
Other dual therapy	3	0.9
Met+SU+DPP-4i (Triple)	21	6.0
Met+SU+TZD (Triple)	1	0.3
Other triple therapy	8	2.3
4 or 4+ therapy	4	1.1
Second-line therapy		
Met (Mono)	3	0.9
SU (Mono)	5	1.4
DPP-4i (Mono)	14	4.0
SGLT-2i (Mono)	7	2.0
Other monotherapy	5	1.4
Met+SU (Dual)	16	4.6
Met+DPP-4i (Dual)	165	47.4
Met+SGLT-2i (Dual)	6	1.7
Met+other (Dual)	5	1.4
SU+TZD (Dual)	4	1.1
Other dual therapy	9	2.6
Met+SU+DPP-4i (Triple)	38	10.9
Met+SU+TZD (Triple)	11	3.2
Other triple therapy	21	6.0
4 or 4+ therapy	33	9.5
Insulin (may also receive oral therapy)	6	1.7

MET = metformin, SU = sulfonylurea, DPP-4i = dipeptidyl peptidase-4 inhibitors, TZD = thiazolidinedione, SGLT-2i = sodium-glucose cotransporter 2 inhibitors.